GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to...

Founded in 2003
Total money raised: $77M

20878 101 Orchard Ridge Drive
Suite 1E


Phone: 240-243-1201

Updated on Jan 23, 2014
GlycoMimetics at CrunchBase
M. James Barrett Chairman of the Board of Directors
Helen Thackray Vice President of Clinical Development and Chief Medical Officer
Rachel K. King Chief Executive Officer & Board of Directors
John Magnani Vice President and Chief Scientific Officer, Board of Directors
Brian Hahn Chief Financial Officer
William Gust Director
Franklin H. Top Director
John J. Baldwin Director
Michael Henos Director

January, 2014

GlycoMimetics Rises as First IPO of 2014

GlycoMimetics IPO
Stock symbol: NASDAQ:GLYC

October, 2013

GlycoMimetics Sets Range For Upcoming IPO Between $14 and $16

GlycoMimetics seeks up to $86 million in IPO

October, 2010

GlycoMimetics raised $39M in a Series A round


December, 2009

GlycoMimetics raised $38M in a Series C round from New Enterprise Associates, Novartis Venture Fund, Anthem Capital Management, Alliance Technology Ventures, and Genzyme Ventures

GlycoMimetics, Inc.: Series C $38M


GlycoMimetics was founded in 2003